AXLRx Book a callCommission

Rare Disease · GCC (Gulf) · In-Market

GCC Pompe Disease Patient Flow Model

400-600 GCC Pompe disease patients, of whom 200-300 are on enzyme replacement therapy. Just 40-60, patients with FVC decline despite alglucosidase already on home ventilation, are the segment this model is built to size.

Assess this report See what's inside ↓ Reviewed by Priyanka, Analyst Last updated July 2026
Market United States United Kingdom GCC (Gulf) Stage

Key takeaways

  • 400-600 estimated total GCC Pompe disease patients, prevalence elevated by consanguinity · GCC Launch Readiness estimate
  • 1:20,000-30,000 GCC Pompe disease incidence vs ~1:40,000 globally · Al-Hassnan Clin Genet 2012 / Saudi NBS Programme 2022
  • 200-300 GCC patients currently on enzyme replacement therapy, the model's treated-population anchor · GCC Launch Readiness estimate
  • 40-60 GCC LOPD patients with FVC decline despite alglucosidase, on home NIV, the switch-eligible inadequate-responder segment · KFSH&RC pulmonology LOPD home NIV programme

400-600 GCC Pompe disease patients are on treatment or awaiting it, and the 40-60 FVC-declining inadequate responders already on home ventilation are the funnel's sharpest commercial target.

Pompe disease in the GCC is a consanguinity-elevated lysosomal storage disorder, with incidence estimated at 1 in 20,000 to 30,000 live births versus roughly 1 in 40,000 globally. Saudi Arabia added Pompe disease to its national newborn-screening panel in 2021, producing an expected 25 to 35 combined GCC infantile-onset detections annually, and the KFSH&RC metabolic genetics programme has treated approximately 120 Pompe patients of all subtypes over 15 years, the region's largest single-centre experience. Late-onset Pompe disease (LOPD) follows a slower path: GCC patients typically present at age 20 to 40, with baseline forced vital capacity already down to 55 to 65% predicted by the time enzyme replacement therapy begins, evidence of a diagnostic delay that runs through rheumatology and neurology before Pompe is confirmed. Total GCC prevalence is estimated at 400 to 600 patients, of whom 200 to 300 are currently on enzyme replacement therapy, the funnel's clearest treated-population anchor point.

Within that treated cohort, 40 to 60 patients, roughly one in five to one in seven of those on enzyme replacement therapy, are inadequate responders: forced vital capacity declining despite alglucosidase and already on home non-invasive ventilation. That segment is the sharpest near-term commercial target for a next-generation ERT, ahead of the broader NPHC step-edit population. A narrower figure of 80 to 120 patients appears in separate GCC payer and competitive intelligence; it tracks the region's long-term-stable, formulary-confirmed enzyme replacement cohort rather than the full 200 to 300 on-treatment estimate used here. The two figures describe overlapping but distinct populations, not competing totals, and this model uses the broader 200 to 300 on-ERT estimate as its funnel anchor.

GCC Pompe disease funnel — from total prevalence to the switch-eligible inadequate-responder pool

THE FUNNEL
Funnel StagePopulationSource
Total GCC Pompe disease patients (all subtypes)400-600GCC Launch Readiness estimate / Al-Hassnan Clin Genet 2012
GCC patients on enzyme replacement therapy200-300GCC Launch Readiness estimate
Long-term-stable, formulary-confirmed ERT cohort (narrower NPHC budget figure)80-120NPHC Pompe programme guidelines 2023
Inadequate responders on alglucosidase (FVC decline, home NIV)40-60KFSH&RC pulmonology LOPD home NIV programme / GCC respiratory disease registry

Sources: Al-Hassnan ZN et al. Clin Genet 2012; Saudi NBS Programme 2022; KFSH&RC Pompe LOPD case series 2015-2022; GCC metabolic disease network registry; NPHC Pompe programme guidelines 2023; KFSH&RC pulmonology LOPD home NIV programme; GCC respiratory disease registry.

What this model answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. How many GCC patients are actually on ERT, and how does that compare to total Pompe disease prevalence? • Total GCC prevalence (400-600) • the 200-300 patients currently on enzyme replacement therapy • how that figure reconciles with the narrower 80-120 long-term-stable formulary cohort cited elsewhere
  2. How large is the inadequate-responder, switch-eligible population, and what defines it? • 40-60 GCC LOPD patients with FVC decline despite alglucosidase, already on home non-invasive ventilation • the NPHC step-edit and ADA-positive waiver pathway • the next-gen ERT switching opportunity this segment represents
  3. What does the live, re-runnable funnel model actually contain? • 8-sheet structure • formulas throughout, zero hardcoded cells • NPHC, KFSH&RC, and GCC metabolic network registry citation per conversion step
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · The Binding Constraint 2 pp
    • Why the 40-60 patient inadequate-responder, home-NIV segment, not total prevalence, sets the addressable near-term pool
    • Reconciling the narrower 80-120 long-term-stable figure against the 200-300 on-ERT estimate
  2. 2 · Disease Burden (E1) — Total Prevalence 3 pp
    • 400-600 total GCC Pompe patients, consanguinity-elevated
    • 1:20,000-30,000 incidence vs ~1:40,000 globally
  3. 3 · Diagnosis & Capture (E2) — Newborn Screening & LOPD Detection 4 pp
    • 25-35 combined GCC IOPD detections annually via the 2021 NBS expansion
    • LOPD presentation at age 20-40 with FVC 55-65% predicted at diagnosis
  4. 4 · Treatment Eligibility (E3) — ERT-Treated Population 3 pp
    • 200-300 GCC patients on enzyme replacement therapy
    • Where the narrower 80-120 long-term-stable formulary cohort sits within that estimate
  5. 5 · Market Access (E4) — Inadequate-Responder Segmentation 3 pp
    • 40-60 patients with FVC decline despite alglucosidase, on home NIV
    • NPHC 12-month step-edit and ADA-positive waiver criteria
  6. 6 · Sensitivity Analysis 3 pp
    • Which assumptions move the eligible pool most
    • Scenario ranges across the prevalence and response-rate inputs
  7. 7 · Year 1·3·5 Projections 4 pp
    • Patient volume by horizon under conservative, base, and aggressive scenarios
    • Revenue translation inputs
  8. 8 · Client Alignment Questions 2 pp
    • The open questions your forecasting team must close before the model is finalised
    • Structured for an internal forecast-review session

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom model delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
Patient Flow Brief — Complete Edition
PDF methodology brief accompanying the 8-sheet funnel model: disease burden, newborn-screening detection, ERT treatment share, and inadequate-responder segmentation for GCC Pompe disease.
XLS
Excel Model
Patient Flow Model — Excel
8-sheet editable funnel model: Strategic Context, Inputs, Model, Projections, Sensitivity, References, Market Context, QC. Formulas throughout, zero hardcoded cells.
PPT
PowerPoint
Executive Readout — PowerPoint
12-15 slide readout deck for forecasting and launch team presentations, formatted to AXLRx design standards.

Get Started

Commission this model

AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC Pompe disease opportunity. Custom model in 72 hours.

  1. 1. Submit your requestSpecify your indication, market, and cohort definition.
  2. 2. Scoping callAXLRx analyst confirms funnel scope and comparator set before building.
  3. 3. DeliveryResearch-verified patient flow model in 72 hours with optional analyst readout.
Assess this report View sample models

How AXLRx builds this model

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and capture (E2), treatment and eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Delivered as a live Excel workbook, not a static table: 8 sheets, formulas throughout, zero hardcoded cells.

GCC Pompe disease sources: Al-Hassnan ZN et al. Clin Genet 2012, the Saudi newborn-screening programme 2022, KFSH&RC Pompe case series and home NIV programme data, the GCC metabolic and respiratory disease network registries, and NPHC Pompe programme guidelines 2023. The narrower 80-120 long-term-stable formulary figure and the broader 200-300 on-ERT estimate are reconciled in this model as overlapping populations, not competing totals.

  • GCC total Pompe disease prevalence estimate (400-600) verified against GCC Launch Readiness figures and Al-Hassnan ZN et al. Clin Genet 2012
  • GCC Pompe disease incidence (1:20,000-30,000) and 2021 newborn-screening expansion verified against the Saudi NBS Programme 2022
  • On-ERT population (200-300) and the narrower 80-120 long-term-stable formulary cohort verified against NPHC Pompe programme guidelines 2023
  • Inadequate-responder segment (40-60 patients on home NIV) verified against KFSH&RC pulmonology LOPD home NIV programme and GCC respiratory disease registry data

Frequently asked questions

Deliverables What formats are included with every model?

Every commissioned Patient Flow Model includes an editable 8-sheet Excel funnel model (Strategic Context, Inputs, Model, Projections, Sensitivity, References, Market Context, QC), a PDF methodology brief, and an optional executive readout deck for forecasting and launch team presentations. A 45-minute analyst readout call is included.

Sources How is the epidemiology evidence verified?

AXLRx builds from primary sources: peer-reviewed clinical literature, Saudi newborn-screening programme data, KFSH&RC case series and home infusion/NIV programme data, and NPHC Pompe programme guidelines, not secondary summaries or market research reports. Every conversion rate is cited to a source and re-runnable in the model, not a black-box number.

Customisation Can I tailor the cohort definition or comparator set?

Yes. The intake form captures your indication, target market, cohort definition, and comparators. A scoping call confirms scope before research starts. Commission via the intake form to start.